These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16529565)

  • 21. [Successful phase III study with serotonin-noradrenaline reuptake inhibitor. Soon a drug to control stress incontinence].
    MMW Fortschr Med; 2004 Feb; 146(7):59. PubMed ID: 15347056
    [No Abstract]   [Full Text] [Related]  

  • 22. The treatment of urinary incontinence with Duloxetine.
    Basu M; Duckett J
    J Obstet Gynaecol; 2008 Feb; 28(2):166-9. PubMed ID: 18393011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Place of duloxetine in the treatment of stress urinary incontinence].
    Rouprêt M; Richard F; Chartier-Kastler E
    Prog Urol; 2005 Sep; 15(4):689-92. PubMed ID: 16459687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innovations in pharmacotherapy for stress urinary incontinence.
    Cannon TW; Yoshimura N; Chancellor MB
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Dec; 14(6):367-72. PubMed ID: 14676995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine versus placebo in the treatment of stress urinary incontinence.
    Norton PA; Zinner NR; Yalcin I; Bump RC;
    Am J Obstet Gynecol; 2002 Jul; 187(1):40-8. PubMed ID: 12114886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurobiology of stress urinary incontinence: new insights and implications for treatment.
    Cardozo L
    J Obstet Gynaecol; 2005 Aug; 25(6):539-43. PubMed ID: 16234136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training.
    Brunenberg DE; Joore MA; Veraart CP; Berghmans BC; van der Vaart CH; Severens JL
    Clin Ther; 2006 Apr; 28(4):604-18. PubMed ID: 16750472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there a place for duloxetine?
    Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence.
    Thor KB
    Urology; 2003 Oct; 62(4 Suppl 1):3-9. PubMed ID: 14550831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
    Rabasseda X
    Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis.
    Li J; Yang L; Pu C; Tang Y; Yun H; Han P
    Int Urol Nephrol; 2013 Jun; 45(3):679-86. PubMed ID: 23504618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How are women with SUI-symptoms treated with duloxetine in real life practice? - preliminary results from a large observational study in Germany.
    Manning M; Gotsch U; Minarzyk A; Quail D; Gross A; Pages I; Methfessel HD; Michel MC
    Int J Clin Pract; 2009 Dec; 63(12):1724-33. PubMed ID: 19930333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
    Westanmo AD; Gayken J; Haight R
    Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Stress incontinence in general practice].
    Krankenpfl J; 2004; 42(7-10):228-9. PubMed ID: 15675390
    [No Abstract]   [Full Text] [Related]  

  • 35. Urinary incontinence: pharmacotherapy options.
    Smith AL; Wein AJ
    Ann Med; 2011; 43(6):461-76. PubMed ID: 21639723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What do we know about duloxetine's mode of action? Evidence from animals to humans.
    Schuessler B
    BJOG; 2006 May; 113 Suppl 1():5-9. PubMed ID: 16529563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic treatment of stress urinary incontinence: expectations for outcome.
    Schuessler B; Baessler K
    Urology; 2003 Oct; 62(4 Suppl 1):31-8. PubMed ID: 14550835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence.
    Kinchen KS; Obenchain R; Swindle R
    Int Urogynecol J Pelvic Floor Dysfunct; 2005; 16(5):337-44. PubMed ID: 15662490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of duloxetine in women with stress urinary incontinence.
    Oelke M; Roovers JP; Michel MC
    BJOG; 2006 May; 113 Suppl 1():22-6. PubMed ID: 16529566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Duloxetine (Yentreve) in the general practice test: recommendation by the experts. Effective and tolerable therapy of symptoms in female stress incontinence].
    Krankenpfl J; 2005; 43(7-10):189-90. PubMed ID: 16515261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.